February 05, 2019
Rose
Scientists have been looking at ketamine's effects on suicidal thoughts for a while now, but no one was biting despite the positive trial results. With the rise of the suicide epidemic, however, the winds might be changing. The first ketamine-based drug, from Johnson & Johnson, could be approved for treatment-resistant depression by March and suicidal thinking within two years. In other public health news: supplements and dementia, gambling, aging and the brain, intimacy, gene-editing and more.
from Kaiser Health News http://bit.ly/2UCycSU
February 05, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Big Pharma Gave Money To Patient Advocacy Groups Opposing Medicare Changes- Why Is This Insurer Sending Massive Checks To Patients? Lawsuit Claims It’s To Put Pressure On Providers To Join Its Network
- Policies To Address Opioid Crisis Would Cause People To Turn To Heroin, Fentanyl In The Short-Term
- Fecal Transplant War Pits Doctors And Pharma Against Each Other In Dirty Battle Over Future Of Treatment
- First Edition: March 4, 2019
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment